Therefore, EGFR is considered an important target of multiple cancer therapies, including non-small cell lung carcinoma (NSCLC), head and neck squamous cell cancers (HNSCCs), glioblastoma, and breast, esophageal, colon, colorectal, anal, lung, gastric, bladder, endometrial, melanoma, prostate, pancreatic and ovarian cancers. The gene discussed is EGFR; the disease is cancer.